Beyond The Numbers: 15 Analysts Discuss Humana Stock
Portfolio Pulse from Benzinga Insights
Humana (NYSE:HUM) has been analyzed by 15 analysts in the last three months, showing a shift from bullish to more cautious ratings. The average 12-month price target for HUM has been lowered to $371.6, indicating a negative sentiment shift. Analysts from firms like RBC Capital, UBS, and Goldman Sachs have adjusted their price targets and ratings, reflecting concerns over Humana's market performance, revenue growth, and financial health. Despite a solid revenue growth rate of 17.93%, Humana's market capitalization, net margin, and debt management raise some concerns.
April 25, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Humana's stock has seen a shift in analyst sentiment, with the average 12-month price target reduced to $371.6, indicating a negative outlook. Despite strong revenue growth, concerns about market capitalization, profitability, and debt levels may impact investor confidence.
The reduction in the average price target by 11.91% and the detailed concerns about Humana's financial health, including its market capitalization, net margin, and debt management, suggest a bearish outlook for HUM in the short term. The strong revenue growth rate is a positive factor, but the overall sentiment among analysts leans towards caution, likely influencing investor perception and potentially leading to a decrease in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100